Wellpoint, J&J and Baxter Among First Eagle Investment’s Biggest Healthcare Stock Positions

Wall St. Watchdog reveals information regarding First Eagle Investment Management’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 54 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $704.029 million.

  • Wellpoint Inc. (NYSE:WLP): On 06/30/2011, First Eagle Investment Management reported holding 3,301,446 shares with a market value of $260,054,890. This comprised 1.23% of the total portfolio. On 09/30/2011, First Eagle Investment Management reported holding 3,417,816 shares with a market value of $223,115,024. This comprised 1.12% of the total portfolio. The net change in shares for this position over the two quarters is 116,370. About Company: WellPoint Inc. is a health benefits company. The Company provides health benefits, dental and vision benefits, pharmacy benefits, life insurance, and life and disability insurance benefits. WellPoint operations include Blue Cross and Blue Shield plans.
  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011, First Eagle Investment Management reported holding 1,583,974 shares with a market value of $105,365,945. This comprised 0.5% of the total portfolio. On 09/30/2011, First Eagle Investment Management reported holding 1,589,759 shares with a market value of $101,251,749. This comprised 0.51% of the total portfolio. The net change in shares for this position over the two quarters is 5,785. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Baxter International Inc. (NYSE:BAX): On 06/30/2011, First Eagle Investment Management reported holding 1,369,300 shares with a market value of $81,733,515. This comprised 0.39% of the total portfolio. On 09/30/2011, First Eagle Investment Management reported holding 1,072,150 shares with a market value of $60,190,500. This comprised 0.3% of the total portfolio. The net change in shares for this position over the two quarters is -297,150. About Company: Baxter International Inc. develops, manufactures, and markets products and technologies related to hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. The Company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and research laboratories.
  • Pfizer Inc. (NYSE:PFE): On 06/30/2011, First Eagle Investment Management reported holding 4,777,214 shares with a market value of $98,410,610. This comprised 0.46% of the total portfolio. On 09/30/2011, First Eagle Investment Management reported holding 3,212,871 shares with a market value of $56,803,560. This comprised 0.28% of the total portfolio. The net change in shares for this position over the two quarters is -1,564,343. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Curis Inc. (NASDAQ:CRIS): On 06/30/2011, First Eagle Investment Management reported holding 17,559,809 shares with a market value of $62,864,115. This comprised 0.3% of the total portfolio. On 09/30/2011, First Eagle Investment Management reported holding 17,822,315 shares with a market value of $56,318,517. This comprised 0.28% of the total portfolio. The net change in shares for this position over the two quarters is 262,506. About Company: Curis, Inc. develops therapeutics for the regeneration and restoration of human tissues and organs.
  • Valeant Pharmaceuticals International (NYSE:VRX): On 06/30/2011, First Eagle Investment Management reported holding 1,589,032 shares with a market value of $82,566,101. This comprised 0.39% of the total portfolio. On 09/30/2011, First Eagle Investment Management reported holding 1,308,842 shares with a market value of $48,584,214. This comprised 0.24% of the total portfolio. The net change in shares for this position over the two quarters is -280,190. About Company: Valeant Pharmaceuticals International, Inc. develops and distributes drugs. The Company develops drugs for unmet medical needs in central nervous system disorders; and distributes generic and branded generic drugs in Latin America and Eastern Europe.
  • Health Net Inc. (NYSE:HNT): On 06/30/2011, First Eagle Investment Management reported holding 1,364,460 shares with a market value of $43,785,522. This comprised 0.21% of the total portfolio. On 09/30/2011, First Eagle Investment Management reported holding 1,438,460 shares with a market value of $34,105,885. This comprised 0.17% of the total portfolio. The net change in shares for this position over the two quarters is 74,000. About Company: Health Net Inc. offers managed health care benefits and products. The Company provides group, individual, Medicare risk, Medicaid, and TRICARE programs. Health Net also offers managed health care products related to behavioral health, dental, vision, and prescription drugs, as well as offers managed health care product coordination and administrative services.
  • Sanofi-aventis (NYSE:SNY): On 06/30/2011, First Eagle Investment Management reported holding 754,462 shares with a market value of $30,306,737. This comprised 0.14% of the total portfolio. On 09/30/2011, First Eagle Investment Management reported holding 754,462 shares with a market value of $24,746,353. This comprised 0.12% of the total portfolio. The net change in shares for this position over the two quarters is 0. About Company: Sanofi-Aventis is a global pharmaceutical company that researches, develops and manufactures prescription pharmaceuticals and vaccines. The Company develops cardiovascular, thrombosis, metabolic disorder, central nervous system, internal medicine and oncology drugs, and vaccines.
  • Amgen Inc. (NASDAQ:AMGN): On 06/30/2011, First Eagle Investment Management reported holding 429,710 shares with a market value of $25,073,578. This comprised 0.12% of the total portfolio. On 09/30/2011, First Eagle Investment Management reported holding 396,220 shares with a market value of $21,776,251. This comprised 0.11% of the total portfolio. The net change in shares for this position over the two quarters is -33,490. About Company: Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
  • Arqule Inc. (NASDAQ:ARQL): On 06/30/2011, First Eagle Investment Management reported holding 1,773,456 shares with a market value of $11,084,100. This comprised 0.05% of the total portfolio. On 09/30/2011, First Eagle Investment Management reported holding 2,019,566 shares with a market value of $10,198,809. This comprised 0.05% of the total portfolio. The net change in shares for this position over the two quarters is 246,110. About Company: ArQule Inc. develops cancer therapeutics based on its proprietary Activated Checkpoint Therapy platform. The Company’s platform is designed to produce small molecule compounds that selectively kill cancer cells while leaving normal cells unharmed. ArQule’s products are intended to be effective against multiple types of cancer.

(Note: Data regarding First Eagle Investment Management’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

More from The Cheat Sheet